Navigation Links
Cellular Dynamics International In-Licenses Key Patent Portfolio for Using Stem Cell-Derived Cells in Drug Testing
Date:7/15/2009

w">Indiana University Research & Technology Corporation said, "As a leader in the pluripotent stem cell field, CDI is a great licensing partner for IUPUI. We are confident CDI will run with this technology, exploiting it to its fullest potential."

The license enables CDI to optimize the process of developing and purifying different cell types created from human pluripotent stem cells, including the company's first commercially available product line, human cardiomyocytes. Under the licensed technology, pluripotent stem cells are engineered to include a selectable "marker." As the stem cells begin to differentiate into different terminal cell types (e.g. heart, blood, neural cells, etc.), the marker allows researchers to identify and select a particular cell type (e.g. heart cells) and produce a highly purified and functional cell population.

The license also covers the use of cardiomyocytes purified through this technology for drug testing. While cardiomyocytes are the company's entree into the market, the company has programs in place for developing multiple cell types, and the Field patents enable the company to develop them into highly purified populations. CDI is using the Field technology in conjunction with the patents it has licensed from the Wisconsin Alumni Research Foundation (WARF), UW-Madison's tech-transfer vehicle, to create a pipeline that mass produces cells for large-scale drug screening campaigns at pharmaceutical companies and for regenerative medicine applications.

In addition the license, which includes patents pending at the European Patent Office, also allows CDI to sublicense to other companies and institutions.

About Cellular Dynamics International, Inc.

Cellular Dynamics International, Inc. (CDI) is a leading developer of next-generation stem cell technologies for dr
'/>"/>

SOURCE Cellular Dynamics International (CDI)
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Cellular Dynamics International Reprograms Blood Cells into Stem Cells
2. iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming
3. Cellular Dynamics International and Roche Expand Existing Cardiotoxicity Screening Agreement
4. New Cellular Bioenergetics Workshops Series Inaugurated by Seahorse Bioscience with Two of the Worlds Leading Bioenergetics Researchers
5. MIT, BU engineer cellular circuits that count events
6. Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
7. Orange and Medic4all Launched the Worlds First Cellular Tele-Health Service
8. MaxCyte Debuts the STX Scalable Transfection System at the A/C/T Assays & Cellular Targets Meeting
9. ChanTest to Highlight the Worlds Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Assays & Cellular Targets Conference, Booth 11
10. Cellumen to Collaborate With the NCTR of the FDA to Apply Cellular Systems Biology (CSB(TM)) to Predictive Toxicology
11. New insights into cellular reprogramming revealed by genomic analysis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...ecently announced that Dr. Dominique Hebrault will...s Analytical Technology (PAT) in Green Chemistry a..., (PRWEB) November 20, 200...chnology (PAT) in Green Chemistry and Green Engine...echnology (PAT) case studies will be presented on ...
(Date:11/19/2009)...rstCall/ -- Omeros Corporation (Nasdaq: OMER ) to...third quarter ended September 30, 2009. For the th...ed a net loss of $3.9 million, or $1.34 per share,...54 per share, for the same period in 2008. For the... reported a net loss of $15.5 million, or $5.29 pe...
(Date:11/19/2009)...irstCall/ -- NeoStem, Inc. (NYSE Amex: NBS ), ann... to its shareholders, discussing the Company,s acq...euticals Holdings, Inc. (CHBP), an integrated bio-...lic of China. The merger gives NeoStem a controlli...Ltd., CHBP,s primary operating subsidiary and a pr...
(Date:11/19/2009)...er 19 MONITORING FORCE GmbH,announ...ibanserin in the,indication treatment-relevant lev...r orphan drug status designation with the European...sia is a complication of the mainstay,treatment in... of those,affected, since it may be disabling for ...
Breaking Biology Technology:Process Analytical Technology (PAT) in Green Chemistry and Green Engineering 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2
... 16 ,Boston Scientific Corporation (NYSE: BSX ) a...the signing of a definitive merger agreement, unde... price of $1.35 per share of,CryoCor, or approxima...elopment agreement, in place since June 2007, to p...n, or "Afib." Afib is the most common,cardiac arrh...
... Inc.,announced today that it has closed the secon...cing. As previously announced, Aisling Capital led...ew investors, the D.E. Shaw,group and Boston Life ...omura Phase4 Ventures, Novartis BioVentures, BioFu... Hentsch, BioVeda Fund and Hercules,Technology Gro...
... Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, ...er and his research group at St. James,s Universit...their work in the April 10 online issue of,Gene Th...Cell Killing by,Oncolytic Reovirus for the Treatme...eovirus effectively kills and replicates,in both h...
Other Biology Technology:Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement 2Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement 3Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement 4Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement 5Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement 6Paratek Pharmaceuticals Completes $40 Million Private Placement to Finance Clinical Programs Including Oral Antibiotic to Combat MRSA and Other Infections 2Paratek Pharmaceuticals Completes $40 Million Private Placement to Finance Clinical Programs Including Oral Antibiotic to Combat MRSA and Other Infections 3Oncolytics Biotech Inc. Announces Gene Therapy Publication on Reovirus Treatment for Melanoma 2
(Date:11/23/2009)...niversity of Alabama at Birmingham (UAB) researche...g medical conditions (co-morbidity) do not explain...ricans compared to Caucasians who also have colon ...Cancer , a journal of the American Cancer Society....o-morbidity are independent predictors of poor sur...
(Date:11/23/2009)...l in unprecedented detail how the ribosome interac...nd guide them toward their destination in biologic...ible fitting (MDFF) to examine the interaction of .... , The first study, in Proceedings of the Nat...signaling between the ribosome and an elongation f...
(Date:11/23/2009)...scoveries about the multiple health benefits of vi... nutrient, increased awareness of the huge numbers...ch and even led to an appreciation of it as "natur...alth of your immune system to prevention of heart ...in D is now seen as one of the most critical nutri...
Breaking Biology News(10 mins):Racial disparity in colon cancer survival not easily explained, UAB researchers say 2Computational microscope peers into the working ribosome 2Computational microscope peers into the working ribosome 3Multiple health concerns surface as winter, vitamin D deficiences arrive 2Multiple health concerns surface as winter, vitamin D deficiences arrive 3Helix BioPharma to Present L DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference 12711 1Helix BioPharma to Present L DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference 12711 2Helix BioPharma to Present L DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference 12711 3Helix BioPharma to Present L DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference 12711 4Helix BioPharma to Present L DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference 12711 5Chemicals in Marijuana Smoke May Harm DNA 49526 1Synutra Annual Report on Form 10 K Includes Going Concern Explanatory Paragraph from Auditor 49524 1Synutra Annual Report on Form 10 K Includes Going Concern Explanatory Paragraph from Auditor 49524 2
... expanding into new territory, successfully aiding...valves in patients too sick to withstand open-ches...th Annual Scientific Sessions of the Society for C..., May 9?2, 2007, in Orlando, FL, patients who were...Valve, Irvine, CA) experienced improvements in bot...
...e use of tissue-engineered scaffolding made of car... naturally, to replace defective cartilage tissue....caffold which is implanted into the body, where ne...he study appears in the journal Artificial Organs....d mice as the study found these scaffolds to be a ...
...e-dose anticlotting medication just before percuta...d risk of heart attack and cardiac death by half, ...cientific Sessions of the Society for Cardiovascul...2007, in Orlando, FL. , Researchers found that gi...e stenting, rather than the standard 300-mg dose, ...
Other Biology News:Percutaneous aortic valve replacement safe, successful in high-risk patients 2High-dose anticlotting drug cuts heart attack, death risk in half 2
...RS are multi-functional mixing devices. Stepping m... solid, heavy-duty durable shaker to provide a uni...ature. Regulated action scale for all modes. Micro...trol time, continuous time, action scale and speed...
Finnigan LTQ FT from Thermo Scientific
PDQuest 10-User Network License from Bio-Rad
Mouse Anti-Human JRKL Monoclonal Antibody, Unconjugated, Clone 4E10 from Abnova Corporation
Biology Products: